Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,599 GBX | +0.98% | -1.84% | +10.26% |
Apr. 17 | GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix | MT |
Apr. 17 | GSK: positive clinical results for gonorrhea | CF |
Sales 2024 * | 31.47B 39.16B | Sales 2025 * | 33.35B 41.5B | Capitalization | 64.7B 80.51B |
---|---|---|---|---|---|
Net income 2024 * | 5.63B 7B | Net income 2025 * | 6.37B 7.93B | EV / Sales 2024 * | 2.44 x |
Net Debt 2024 * | 12.16B 15.13B | Net Debt 2025 * | 8.93B 11.11B | EV / Sales 2025 * | 2.21 x |
P/E ratio 2024 * |
11.5
x | P/E ratio 2025 * |
10.2
x | Employees | 70,212 |
Yield 2024 * |
3.84% | Yield 2025 * |
4.11% | Free-Float | 92.58% |
Latest transcript on GSK plc
1 day | +0.90% | ||
1 week | -2.92% | ||
Current month | -6.62% | ||
1 month | -4.14% | ||
3 months | +2.04% | ||
6 months | +9.94% | ||
Current year | +10.02% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +1.40% | - | |
2.51% | 5 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1,599 | +0.98% | 3 760 947 |
24-04-18 | 1,584 | -0.41% | 5,914,111 |
24-04-17 | 1,590 | -1.27% | 7,387,602 |
24-04-16 | 1,610 | -2.01% | 8,908,709 |
24-04-15 | 1,643 | 0.00% | 5,188,791 |
Delayed Quote London S.E., April 19, 2024 at 10:45 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.02% | 80.65B | |
+25.59% | 672B | |
+23.92% | 550B | |
-6.44% | 351B | |
+14.74% | 317B | |
+7.00% | 292B | |
+2.96% | 211B | |
+0.33% | 203B | |
-11.20% | 144B | |
-7.75% | 141B |
- Stock Market
- Equities
- GSK Stock